Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK.

ABSTRACT: PURPOSE:Our objective was to estimate the economic outcomes of using mirabegron versus antimuscarinics in the treatment of patients with overactive bladder (OAB) from a societal perspective in the UK. MATERIALS AND METHODS:A Markov model was developed using Microsoft Excel®. The time horizon and cycle length are 12 and 1 months, respectively; and the hypothetical cohort size 100 patients. Antimuscarinic comparators are fesoterodine, oxybutynin extended release (ER) and immediate release (IR), solifenacin, tolterodine ER/IR, trospium ER/IR, darifenacin and flavoxate. Model inputs included real-world treatment patterns data, healthcare resource use (e.g. clinic visits) and direct and indirect costs (e.g. drug acquisition and productivity loss). Model outputs included patient disposition, hea

SUBMITTER: Nazir J 

PROVIDER: S-EPMC5689035 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature